Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$69.57 -1.0%	$69.15	$47.86 ▼ $107.37	$3.86B	0.28	657,980 shs	247,517 shs
AKRO Akero Therapeutics	$46.68 -0.6%	$50.74	$21.34 ▼ $58.40	$3.73B	-0.28	1.38 million shs	290,893 shs
LNTH Lantheus	$54.98 -0.9%	$69.69	$47.25 ▼ $118.21	$3.74B	0.14	1.20 million shs	705,221 shs
NUVB Nuvation Bio	$2.98 +1.9%	$2.36	$1.54 ▼ $3.45	$1.02B	1.35	4.25 million shs	1.83 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	+0.50%	-2.12%	+0.37%	+10.51%	+1.37%
AKRO Akero Therapeutics	-2.59%	-2.80%	-1.16%	-8.00%	+76.27%
LNTH Lantheus	-2.36%	-6.19%	-23.13%	-26.50%	-49.41%
NUVB Nuvation Bio	-1.02%	+6.58%	+18.74%	+37.50%	-10.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACLX Arcellx	2.1233 of 5 stars	3.6	0.0	0.0	3.7	2.5	0.0
AKRO Akero Therapeutics	4.0811 of 5 stars	3.5	2.0	4.7	4.2	0.8	0.0
LNTH Lantheus	4.7748 of 5 stars	4.4	1.0	4.2	3.2	2.5	1.9
NUVB Nuvation Bio	2.2225 of 5 stars	3.6	1.0	0.0	2.2	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACLX Arcellx	3.13	Buy	$114.31	64.32% Upside
AKRO Akero Therapeutics	3.00	Buy	$81.57	74.75% Upside
LNTH Lantheus	2.71	Moderate Buy	$105.50	91.88% Upside
NUVB Nuvation Bio	3.17	Buy	$7.33	146.50% Upside

Current Analyst Ratings Breakdown

Latest NUVB, LNTH, ACLX, and AKRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Hold	$111.00 ➝ $63.00
8/8/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
8/7/2025	LNTH Lantheus	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$112.00 ➝ $73.00
8/7/2025	LNTH Lantheus	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$120.00 ➝ $70.00
8/4/2025	AKRO Akero Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
8/4/2025	ACLX Arcellx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/4/2025	AKRO Akero Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$76.00
7/31/2025	ACLX Arcellx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$93.00 ➝ $133.00
7/16/2025	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACLX Arcellx	$107.94M	35.74	N/A	N/A	$7.07 per share	9.84
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$12.82 per share	N/A
LNTH Lantheus	$1.53B	2.44	$6.86 per share	8.01	$17.16 per share	3.20
NUVB Nuvation Bio	$14.36M	70.93	N/A	N/A	$1.09 per share	2.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACLX Arcellx	-$107.35M	-$3.42	N/A	N/A	N/A	-329.93%	-43.04%	-27.41%	11/6/2025 (Estimated)
AKRO Akero Therapeutics	-$252.06M	-$2.00	N/A	N/A	N/A	N/A	-15.84%	-14.59%	11/14/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.76	14.62	8.71	N/A	17.82%	34.06%	19.10%	11/5/2025 (Estimated)
NUVB Nuvation Bio	-$567.94M	-$0.63	N/A	N/A	N/A	-1,413.43%	-46.14%	-36.04%	11/5/2025 (Estimated)

Latest NUVB, LNTH, ACLX, and AKRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.97	-$0.86	+$0.11	-$0.86	N/A	N/A
8/7/2025	Q2 2025	ACLX Arcellx	-$1.03	-$0.94	+$0.09	-$0.94	$16.76 million	$7.55 million
8/7/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	-$0.17	N/A	-$0.17	$0.42 million	$4.83 million
8/6/2025	Q2 2025	LNTH Lantheus	$1.65	$1.57	-$0.08	$1.12	$389.69 million	$378.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACLX Arcellx	N/A	3.81	3.81
AKRO Akero Therapeutics	0.02	12.66	12.66
LNTH Lantheus	0.49	4.29	4.07
NUVB Nuvation Bio	0.13	9.39	9.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACLX Arcellx	96.03%
AKRO Akero Therapeutics	N/A
LNTH Lantheus	99.06%
NUVB Nuvation Bio	61.67%

Insider Ownership

Company	Insider Ownership
ACLX Arcellx	8.35%
AKRO Akero Therapeutics	7.07%
LNTH Lantheus	1.50%
NUVB Nuvation Bio	29.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACLX Arcellx	80	55.46 million	50.83 million	Optionable
AKRO Akero Therapeutics	30	79.99 million	74.33 million	Optionable
LNTH Lantheus	700	67.99 million	66.97 million	Optionable
NUVB Nuvation Bio	60	342.27 million	239.83 million	Optionable

NUVB, LNTH, ACLX, and AKRO Headlines

Recent News About These Companies

Nuvation Bio: What To Expect From IBTROZI Launch?

August 28 at 12:16 PM | seekingalpha.com

Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of "Buy" from Analysts

August 28 at 5:21 AM | marketbeat.com

Nuvation Bio to Participate in Upcoming Investor Conferences

August 27 at 4:05 PM | businesswire.com

Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?

August 27 at 10:55 AM | zacks.com

H.C. Wainwright Reiterates a Buy Rating on Nuvation Bio (NUVB)

August 26 at 2:19 AM | msn.com

Nuvation Bio Inc. $NUVB Shares Acquired by Algert Global LLC

August 24, 2025 | marketbeat.com

Wall Street Zen Upgrades Nuvation Bio (NYSE:NUVB) to Hold

August 18, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Trading 9.7% Higher - Still a Buy?

August 15, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Announces Quarterly Earnings Results

August 11, 2025 | marketbeat.com

Royal Bank Of Canada Increases Nuvation Bio (NYSE:NUVB) Price Target to $7.00

August 10, 2025 | marketbeat.com

Wedbush Reaffirms Their Buy Rating on Nuvation Bio (NUVB)

August 10, 2025 | theglobeandmail.com

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

August 10, 2025 | theglobeandmail.com

Wall Street Zen Downgrades Nuvation Bio (NYSE:NUVB) to Sell

August 10, 2025 | marketbeat.com

H.C. Wainwright Sticks to Their Buy Rating for Nuvation Bio (NUVB)

August 9, 2025 | theglobeandmail.com

NUVB Sales Jump 1,043% on Drug Launch

August 7, 2025 | aol.comA

Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates

August 7, 2025 | zacks.com

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | gurufocus.com

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | businesswire.com

Nuvation Bio Inc. (NYSE:NUVB) Given Average Rating of "Buy" by Brokerages

August 2, 2025 | marketbeat.com

Nuvation Bio (NUVB)’s Taletrectinib Selected as Preferred Agent for Cancer Treatment

August 1, 2025 | finance.yahoo.com

GSA Capital Partners LLP Has $1.16 Million Stock Position in Nuvation Bio Inc. (NYSE:NUVB)

August 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB, LNTH, ACLX, and AKRO Company Descriptions

Arcellx NASDAQ:ACLX

$69.56 -0.69 (-0.98%)

Closing price 03:59 PM Eastern

Extended Trading

$69.44 -0.13 (-0.18%)

As of 04:10 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Akero Therapeutics NASDAQ:AKRO

$46.68 -0.26 (-0.55%)

Closing price 03:59 PM Eastern

Extended Trading

$46.65 -0.03 (-0.06%)

As of 04:10 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Lantheus NASDAQ:LNTH

$54.98 -0.52 (-0.94%)

Closing price 03:59 PM Eastern

Extended Trading

$54.89 -0.09 (-0.17%)

As of 04:10 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Nuvation Bio NYSE:NUVB

$2.98 +0.06 (+1.88%)

Closing price 03:59 PM Eastern

Extended Trading

$2.89 -0.09 (-2.99%)

As of 04:11 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time